Skip to main content

Purification and Assay of Kinase-Active EGF Receptor From Mammalian Cells by Immunoaffinity Chromatography

  • Protocol
Epidermal Growth Factor

Part of the book series: Methods in Molecular Biology ((MIMB,volume 327))

Abstract

The epidermal growth factor (EGF) receptor possesses intrinsic protein-tyrosine kinase activity, and both overexpressed wild-type and mutated forms have been associated with many types of cancers. Therefore, understanding the mechanisms that modulate receptor activity and function is essential to the development of treatments for many of these cancers. However, to address this issue by either conventional or high-throughput screening methods requires the availability of large amounts of highly purified and active EGF receptor.

The technique described in this chapter utilizes immunoaffinity chromatography, which allows for the isolation of highly purified and active preparations of EGF receptor. By immobilizing an antibody that recognizes the ligand-binding domain of the receptor to Sepharose beads, the receptor can be eluted specifically from the antibody by the addition of EGF. This association establishes a unique interaction that ensures the isolation of a highly enriched preparation of EGF receptor. This protocol allows for the purification of large or small batches of receptor that retain their kinase activity. Additionally, this chapter reports on the subsequent steps necessary to characterize the receptor: kinase activity, mass, purity, and the ability of the receptor to undergo autophosphorylation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lynch T. J., Bell D. W., Sordella R., et al. (2004) Activating mutations in theepidermal growth factor receptor underlying responsiveness of non-small-celllung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139.

    Article  PubMed  CAS  Google Scholar 

  2. Carpenter G. and Cohen S. (1990) Epidermal growth factor. J. Biol. Chem. 265, 7709–7712.

    PubMed  CAS  Google Scholar 

  3. Bertics P. J. and Gill G. N. (1985) Self-phosphorylation enhances the proteintyrosinekinase activity of the epidermal growth factor receptor. J. Biol. Chem. 260, 14,642–14,647.

    PubMed  CAS  Google Scholar 

  4. Buday L. and Downward J. (1993) Epidermal growth factor regulates p21rasthrough the formation of a complex of receptor, Grb2 adapter protein, and Sosnucleotide exchange factor. Cell 73, 611–620.

    Article  PubMed  CAS  Google Scholar 

  5. Wang X. J., Liao H. J., Chattopadhyay A., Carpenter G. (2001) EGF-dependenttranslocation of green fluorescent protein-tagged PLC-gamma1 to theplasma membrane and endosomes. Exp. Cell. Res. 267, 28–36.

    Article  PubMed  CAS  Google Scholar 

  6. Zhu G., Decker S.J., Saltiel A. R. (1992) Direct analysis of the binding ofSrc-homology 2 domains of phospholipase C to the activated epidermal growthfactor receptor. Proc. Natl. Acad. Sci. USA 89, 9559–9563.

    Article  PubMed  CAS  Google Scholar 

  7. Pao W., Miller V., Zakowski M., et al. (2004) EGF receptor gene mutations arecommon in lung cancers from “never smokers” and are associated with sensitivityof tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13,306–13,311.

    Article  PubMed  CAS  Google Scholar 

  8. Sordella R., Bell D. W., Haber D., Settleman J. (2004) Gefitinib-sensitizingEGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167.

    Article  PubMed  CAS  Google Scholar 

  9. Paez J. G., Janne P. A., Lee J. C., et al. (2004) EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science 304, 1497–1500.

    Article  PubMed  CAS  Google Scholar 

  10. Weber W., Bertics P.J., Gill G. N. (1984) mmunoaffinity purification ofthe epidermal growth factor receptor. Stoichiometry of binding and kinetics ofself-phosphorylation. J. Biol. Chem. 259, 14,631–14,636.

    PubMed  CAS  Google Scholar 

  11. Gronowski A. M. and Bertics P. J. (1993) Evidence for the potentiation of epidermalgrowth factor receptor tyrosine kinase activity by association with the detergent-insoluble cellular cytoskeleton: analysis of intact and carboxy-terminallytruncated receptors. Endocrinology 133, 2838–2846.

    Article  PubMed  CAS  Google Scholar 

  12. Beebe J. A., Wiepz G. J., Guadarrama A. G., Bertics P.J., Burke, T. J.(2003) A carboxyl-terminal mutation of the epidermal growth factor receptor alterstyrosine kinase activity and substrate specificity as measured by a fluorescencepolarization assay. J. Biol. Chem. 278, 26,810–26,816.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc.

About this protocol

Cite this protocol

Wiepz, G.J., Guadaramma, A.G., Fulgham, D.L., Bertics, P.J. (2006). Purification and Assay of Kinase-Active EGF Receptor From Mammalian Cells by Immunoaffinity Chromatography. In: Patel, T.B., Bertics, P.J. (eds) Epidermal Growth Factor. Methods in Molecular Biology, vol 327. Humana Press. https://doi.org/10.1385/1-59745-012-X:25

Download citation

  • DOI: https://doi.org/10.1385/1-59745-012-X:25

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-421-0

  • Online ISBN: 978-1-59745-012-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics